Achievements and challenges of adoptive T cell therapy with tumor-infiltrating or blood-derived lymphocytes for metastatic melanoma: what is needed to achieve standard of care? (Q38237522)

From Wikidata

Jump to navigation Jump to search

scientific article published on 07 August 2014

Language	Label	Description	Also known as
English	Achievements and challenges of adoptive T cell therapy with tumor-infiltrating or blood-derived lymphocytes for metastatic melanoma: what is needed to achieve standard of care?	scientific article published on 07 August 2014

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

Achievements and challenges of adoptive T cell therapy with tumor-infiltrating or blood-derived lymphocytes for metastatic melanoma: what is needed to achieve standard of care? (English)

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

metastatic melanoma

1 reference

based on heuristic

inferred from title

Inge Marie Svane

1

object named as

Inge Marie Svane

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

author name string

Els M Verdegaal

2

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

publication date

7 August 2014

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

Cancer Immunology, Immunotherapy

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

63

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

1081-1091

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

Cancer immunotherapy comes of age

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1580-5

21 January 2018

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1580-5

21 January 2018

Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1580-5

21 January 2018

Analysis of Vδ1 T cells in clinical grade melanoma-infiltrating lymphocytes

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1580-5

21 January 2018

A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1580-5

21 January 2018

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1580-5

21 January 2018

Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1580-5

21 January 2018

Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1580-5

21 January 2018

Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1580-5

21 January 2018

Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1580-5

21 January 2018

Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1580-5

21 January 2018

Tumor Infiltrating Lymphocyte Therapy for Metastatic Melanoma: Analysis of Tumors Resected for TIL

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1580-5

21 January 2018

Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1580-5

21 January 2018

CD8+ Enriched “Young” Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1580-5

21 January 2018

Establishment and large-scale expansion of minimally cultured "young" tumor infiltrating lymphocytes for adoptive transfer therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1580-5

21 January 2018

Characterization and comparison of 'standard' and 'young' tumour-infiltrating lymphocytes for adoptive cell therapy at a Danish translational research institution.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1580-5

21 January 2018

Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1580-5

21 January 2018

Clinical scale rapid expansion of lymphocytes for adoptive cell transfer therapy in the WAVE® bioreactor

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1580-5

21 January 2018

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1580-5

21 January 2018

Methods to improve adoptive T-cell therapy for melanoma: IFN-γ enhances anticancer responses of cell products for infusion

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1580-5

21 January 2018

Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1580-5

21 January 2018

Adoptive T cell therapy for cancer in the clinic

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1580-5

21 January 2018

Simplified protocol for clinical-grade tumor-infiltrating lymphocyte manufacturing with use of the Wave bioreactor.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1580-5

21 January 2018

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1580-5

21 January 2018

Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1580-5

21 January 2018

Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1580-5

21 January 2018

A full GMP process to select and amplify epitope-specific T lymphocytes for adoptive immunotherapy of metastatic melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1580-5

21 January 2018

Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1580-5

21 January 2018

Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1580-5

21 January 2018

Treatment of metastatic melanoma with autologous Melan-A/MART-1-specific cytotoxic T lymphocyte clones.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1580-5

21 January 2018

Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1580-5

21 January 2018

Interferon-gamma reduces melanosomal antigen expression and recognition of melanoma cells by cytotoxic T cells

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1580-5

21 January 2018

BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1580-5

21 January 2018

Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1580-5

21 January 2018

TIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma patients.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1580-5

21 January 2018

Successful treatment of metastatic melanoma by adoptive transfer of blood-derived polyclonal tumor-specific CD4+ and CD8+ T cells in combination with low-dose interferon-alpha

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1580-5

21 January 2018

Mutated PPP1R3B is recognized by T cells used to treat a melanoma patient who experienced a durable complete tumor regression.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1580-5

21 January 2018

Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1580-5

21 January 2018

Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1580-5

21 January 2018

Fludarabine modulates immune response and extends in vivo survival of adoptively transferred CD8 T cells in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1580-5

21 January 2018

Establishment of antitumor memory in humans using in vitro-educated CD8+ T cells

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1580-5

21 January 2018

Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1580-5

21 January 2018

Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1580-5

21 January 2018

Myeloid-derived suppressor cells are associated with disease progression and decreased overall survival in advanced-stage melanoma patients

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1580-5

21 January 2018

Overcoming immunosuppression in the melanoma microenvironment induced by chronic inflammation

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1580-5

21 January 2018

Chemotherapeutic targeting of cancer-induced immunosuppressive cells

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1580-5

21 January 2018

White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1580-5

21 January 2018

Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1580-5

21 January 2018

BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1580-5

21 January 2018

BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1580-5

21 January 2018

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1580-5

21 January 2018

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1580-5

21 January 2018

Nivolumab plus ipilimumab in advanced melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1580-5

21 January 2018

Which drug, and when, for patients with BRAF-mutant melanoma?

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1580-5

21 January 2018

Identifiers

10.1007/S00262-014-1580-5

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38237522&oldid=2201450390"